OncoMatch/Clinical Trials/NCT05950139
Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC
Is NCT05950139 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies Peptide vaccine for nsclc stage iv.
Treatment: Peptide vaccine — The purpose of this study is to evaluate the safety of a cancer peptide vaccine to prevent or delay acquired resistance in advanced ALK+ lung cancer patients currently on ALK targeted therapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: ALK rearrangement
Documented ALK rearrangement as detected by: (1) fluorescence in situ hybridization (FISH), (2) immuno-histochemistry (IHC), (3) tissue next-generation sequencing (NGS), or (4) circulating tumor DNA (ctDNA) NGS
Required: ALK acquired resistance alterations targeted by the study vaccine
No known presence of the specific ALK acquired resistance alterations targeted by the study vaccine
Disease stage
Required: Stage IV
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: ALK inhibitor (crizotinib, ceritinib, alectinib, brigatinib, lorlatinib) — ongoing
Ongoing treatment with crizotinib, ceritinib, alectinib, brigatinib, or lorlatinib with at least stable disease ≥ 4 months
Cannot have received: cytotoxic chemotherapy
Cytotoxic chemotherapy within 14 days of first dose of study vaccine or concurrent with study vaccine
Cannot have received: anti-neoplastic immunotherapy
Anti-neoplastic immunotherapy within 28 days of first dose of study vaccine or concurrent with study vaccine
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Johns Hopkins University · Baltimore, Maryland
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify